Alessandra Ferzoco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alessandra Ferzoco has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Aaron Prodeus
Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
1 shared publication - Amanda Sparkes
Sunnybrook Research Institute
1 shared publication - Aws Abdul-Wahid
Sunnybrook Research Institute, Toronto, Ontario, Canada
1 shared publication - Jean Gariépy
Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
1 shared publication - Marzena Cydzik
Sunnybrook Research Institute, Toronto, Ontario, Canada
1 shared publication - Mays Alwash
Sunnybrook Research Institute, Toronto, Ontario, Canada
1 shared publication
Latest Publications
- Open Access
- 21 September 2017
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 2 (18)
VISTA.COMP — an engineered checkpoint receptor agonist that potently suppresses T cell–mediated immune responses
V-domain immunoglobulin suppressor of T cell activation (VISTA) is a recently discovered immune checkpoint ligand that functions to suppress T cell activity. The therapeutic potential of activating this immune checkpoint pathway to reduce inflammatory responses remains untapped, largely due to the inability to derive agonists targeting its unknown receptor. A dimeric construct of the IgV domain of VISTA (VISTA-Fc) was shown to suppress the activation of T cells in vitro. However, this effect required its immobilization on a solid surface, suggesting that VISTA-Fc may display limited efficacy as a VISTA-receptor agonist in vivo. Herein, we have designed a stable pentameric VISTA construct (VISTA.COMP) by genetically fusing its IgV domain to the pentamerization domain from the cartilage oligomeric matrix protein (COMP). In contrast to VISTA-Fc, VISTA.COMP does not require immobilization to inhibit the proliferation of CD4 + T cells undergoing polyclonal activation. Furthermore, we show that VISTA.COMP, but not VISTA-Fc, functions as an immunosuppressive agonist in vivo capable of prolonging the survival of skin allografts in a mouse transplant model as well as rescuing mice from acute concanavalin-A–induced hepatitis. Collectively, we believe our data demonstrate that VISTA.COMP is a checkpoint receptor agonist and the first agent to our knowledge targeting the putative VISTA-receptor to suppress T cell–mediated immune responses.
- 21 September 2017
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 2 (18)
Open AccessVISTA.COMP — an engineered checkpoint receptor agonist that potently suppresses T cell–mediated immune responses
V-domain immunoglobulin suppressor of T cell activation (VISTA) is a recently discovered immune checkpoint ligand that functions to suppress T cell activity. The therapeutic potential of activating this immune checkpoint pathway to reduce inflammatory responses remains untapped, largely due to the inability to derive agonists targeting its unknown receptor. A dimeric construct of the IgV domain of VISTA (VISTA-Fc) was shown to suppress the activation of T cells in vitro. However, this effect required its immobilization on a solid surface, suggesting that VISTA-Fc may display limited efficacy as a VISTA-receptor agonist in vivo. Herein, we have designed a stable pentameric VISTA construct (VISTA.COMP) by genetically fusing its IgV domain to the pentamerization domain from the cartilage oligomeric matrix protein (COMP). In contrast to VISTA-Fc, VISTA.COMP does not require immobilization to inhibit the proliferation of CD4 + T cells undergoing polyclonal activation. Furthermore, we show that VISTA.COMP, but not VISTA-Fc, functions as an immunosuppressive agonist in vivo capable of prolonging the survival of skin allografts in a mouse transplant model as well as rescuing mice from acute concanavalin-A–induced hepatitis. Collectively, we believe our data demonstrate that VISTA.COMP is a checkpoint receptor agonist and the first agent to our knowledge targeting the putative VISTA-receptor to suppress T cell–mediated immune responses.